http://www.fpnotebook.com/
RivastigmineAka: Exelon
- See Also
- Tacrine (Cognex)
- Donepezil (Aricept)
- Indications
- Alzheimer's Disease related Dementia
- Mechanism
- Carbamate-based noncompetitive cholinesterase inhibitor
- Inhibits butyrylcholinesterase and acetylcholinesterase
- Increases cholinergic transmission
- Pharmacokinetics
- Peak: 1 hour
- Duration: 10 hours
- Drug Interactions
- No significant drug interactions
- Efficacy
- Modestly improves scores on neuropsychological tests
- Benefits decrease after 40 weeks of treatment
- Adverse Effects
- Nausea or Vomiting
- Diarrhea
- Abdominal Pain
- Anorexia
- Weight loss
- No hepatotoxicity risk (contrast with Tacrine)
- Dosing
- Initial: 1.5 mg PO bid with food
- Increase dose by 1.5 mg every 2 weeks up to 6 mg bid
- Cost
- (2003) Red Book: $130/month
- References
- (2000) Med Lett Drugs Ther 42(1089):93
- Corey-Bloom (1998) Int J Geriatr Psychopharm 1:55
- Rosler (1999) BMJ 318:633
|
|---|
| Concepts | Organic Chemical (T109)
, Pharmacologic Substance (T121)
|
| English | rivastigmine, RIVASTIGMINE PREPARATION |
| Spanish | rivastigmina |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
Navigation Tree